Isoptin Retard (Verapamil Hydrochloride)

• Verapamil is indicated for several cardiovascular conditions that involve abnormal vascular tone or cardiac conduction.
• Hypertension: reduces systemic blood pressure by relaxing arterial smooth muscle, decreasing peripheral resistance, and lowering cardiac output.
• Angina pectoris: alleviates exertional chest pain by decreasing myocardial contractility and oxygen consumption, and by dilating coronary arteries.
• Cardiac arrhythmias (e.g., supraventricular tachycardia): controls abnormal heart rhythms by slowing atrioventricular nodal conduction and prolonging refractory periods.

• Verapamil blocks L‑type calcium channels in cardiac and vascular smooth‑muscle cells. By inhibiting calcium influx, it reduces myocardial contractility, slows conduction through the atrioventricular node, and causes vasodilation of peripheral arteries. The combined effect lowers heart rate, decreases cardiac workload, and lowers systemic vascular resistance, contributing to its antihypertensive, anti‑anginal, and anti‑arrhythmic actions. Additionally, verapamil may modestly prolong the QT interval by affecting repolarization.

Verapamil may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Constipation: reduced gastrointestinal motility leading to hard stools.
• Dizziness or light‑headedness: due to blood pressure lowering.
• Headache: mild vascular headache.
• Peripheral edema: fluid accumulation in lower limbs.

Serious or Rare Side Effects

• Severe bradycardia: markedly slowed heart rate that may require medical attention.
• Heart block: impairment of atrioventricular conduction, potentially leading to syncope.
• Hypotension: abrupt drop in blood pressure causing fainting.

When prescribing verapamil, clinicians should consider several precautionary measures to ensure patient safety.

• Assess cardiac function: evaluate baseline heart rate and conduction abnormalities before initiation.
• Review concomitant medications: avoid drugs that may exacerbate bradycardia or hypotension.
• Monitor blood pressure: regular checks during dose titration.
• Caution in hepatic impairment: dose adjustments may be needed due to altered metabolism.
• Avoid use in patients with known hypersensitivity to verapamil or related calcium channel blockers.
• Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Verapamil interacts with several medicines, influencing its plasma levels or enhancing pharmacodynamic effects.

Major Interactions (Avoid)

• Beta‑blockers (e.g., metoprolol): combined use can cause profound bradycardia and AV block.
• Digoxin: verapamil raises digoxin concentrations, increasing risk of toxicity.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may markedly increase verapamil levels, leading to severe hypotension.

Moderate Interactions (Monitor Closely)

• Calcium channel blocker combinations (e.g., diltiazem): additive effects on heart rate and blood pressure.
• Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy.
• Antidiabetic agents (e.g., insulin, sulfonylureas): may enhance hypoglycemic effect.